Expand QNRX Menu
QNRX MENU

QNRX Latest Press Releases

-- July 9, 2026 --

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome Globe Newswire 8:30 AM

-- June 30, 2026 --

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome Globe Newswire 8:30 AM

-- June 23, 2026 --

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton Syndrome Globe Newswire 8:30 AM

-- June 18, 2026 --

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 Globe Newswire 8:30 AM

-- June 16, 2026 --

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program Globe Newswire 8:30 AM

-- June 4, 2026 --

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome Globe Newswire 8:30 AM

-- June 2, 2026 --

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome Globe Newswire 8:30 AM

-- May 7, 2026 --

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results Globe Newswire 8:30 AM

-- April 30, 2026 --

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 Globe Newswire 8:30 AM

-- April 28, 2026 --

CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs Globe Newswire 12:02 PM
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs Globe Newswire 8:30 AM

-- March 26, 2026 --

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results Globe Newswire 8:30 AM

-- March 25, 2026 --

Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome Globe Newswire 8:30 AM

-- March 19, 2026 --

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 Globe Newswire 8:30 AM

-- March 11, 2026 --

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome Globe Newswire 8:30 AM

-- February 26, 2026 --

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes